The Commission has today adopted a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, […]
• 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential […]
• Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, […]
The Commission announced today that 8 large-scale research projects, aimed at developing treatments and diagnostics for the coronavirus,were selected in a fast-track call for proposals, […]
The European Commission, EMA and the European medicines regulatory network have developed a Q&A document to provide guidance to stakeholders on adaptations to the regulatory […]
Coronavirus: Statement by Ursula von der Leyen, President of the European Commission, on guidelines to ensure supply and availability of medicines here On 8 April […]
The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new recommendations for sponsors on how to manage […]
Copyright © 2022 | WordPress Theme by MH Themes
